Australia is welcome a groundbreaking therapy for obesity: Retatrutide. This dual agonist – targeting on both GLP-1 and GIP receptors – has significant efficacy in clinical trials, pointing to substantial reductions in BMI. While approval remains with Australian regulators, many individuals deali